Pharmaverse Podcast

Episode 12: The Future of Immunotherapy with Mark Frohlich

Michael Pietrack Season 1 Episode 11

We are thrilled to be joined this week by Mark Frohlich, a Harvard-trained medical oncologist and CEO of Indapta on the Pharmaverse! He discusses his experience in the pharmaceutical industry and the challenges and advancements in immunotherapy. He emphasizes the importance of understanding the immune system and the need for cryopreservation in cell therapies. Frohlich also discusses the future of immunotherapy, including the integration of different approaches and the role of artificial intelligence. "For cell therapies, it needs to be cryopreserved to be really commercially viable." As a CEO, he highlights the importance of focusing on tasks that only he can do, giving honest feedback, and seeking out mentors for career development. 


 Key Points: 

👨‍⚕️ Understanding the immune system is crucial in developing effective immunotherapies. 

💉Cryopreservation is essential for the commercial viability of cell therapies. 🔜The future of immunotherapy lies in integrating different approaches and leveraging artificial intelligence. 

✋As a CEO, focus on tasks that only you can do and delegate other responsibilities. 🔰Give honest and direct feedback to help employees perform at their best. 

📚Seek out mentors for guidance and career development. 


 Chapters 

00:00 Introduction to Mark Froehlich and his Background in Immunotherapy 

03:07 The Future of Immunotherapy: Integration and AI 

06:18 Mark Froehlich's Transition from Engineering to Medicine 

08:00 The Role of Engineering in Drug Development 

11:14 Leadership Best Practices for CEOs 

13:05 The Importance of Honest Feedback

People on this episode